Literature DB >> 2937503

5-Carboxamidotryptamine is a selective agonist at 5-hydroxytryptamine receptors mediating vasodilatation and tachycardia in anaesthetized cats.

H E Connor, W Feniuk, P P Humphrey, M J Perren.   

Abstract

We have attempted to characterize the 5-hydroxytryptamine (5-HT) receptors mediating bronchoconstriction, vasodilatation, vasodepression and tachycardia in anaesthetized cats following bilateral vagosympathectomy and beta-adrenoceptor blockade with propranolol. 5-HT (1-100 micrograms/kg-1 i.v.) caused dose-related bronchoconstriction and tachycardia but variable and complex effects on diastolic blood pressure and carotid arterial vascular resistance. In contrast, 5-carboxamidotryptamine (5-CT; 0.01-1 micrograms kg-1 i.v.) caused consistent, dose-related decreases in diastolic blood pressure and carotid arterial vascular resistance and increases in heart rate. 5-CT did not cause bronchoconstriction. The 5-HT-induced bronchoconstriction was dose-dependently antagonized by methiothepin, methysergide and ketanserin (10-100 micrograms kg-1 i.v.). The highest doses used of these antagonists did not antagonize bronchoconstriction induced by prostaglandin F2 alpha. The high potency of all three antagonists indicate a 5-HT2-receptor mediated effect. The 5-HT- and 5-CT-induced tachycardia as well as the 5-CT-induced vasodepressor and carotid arterial vasodilator responses were dose-dependently antagonized by low doses of methiothepin (10-100 micrograms kg-1 i.v.) and by high doses of methysergide (100-1000 micrograms kg-1 i.v.) but were little affected by ketanserin in doses up to 1000 micrograms kg-1 i.v. These selective effects of 5-CT appear to be mediated by '5-HT1-like' receptors.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2937503      PMCID: PMC1916538          DOI: 10.1111/j.1476-5381.1986.tb10832.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  18 in total

1.  The action of histamine and 5-hydroxytryptamine on isolated mammalian atria.

Authors:  U TRENDELENBURG
Journal:  J Pharmacol Exp Ther       Date:  1960-12       Impact factor: 4.030

2.  Contributions to the physiology of the lungs: Part I. The bronchial muscles, their innervation, and the action of drugs upon them.

Authors:  W E Dixon
Journal:  J Physiol       Date:  1903-03-16       Impact factor: 5.182

3.  Ketanserin--a novel antihypertensive drug?

Authors:  P P Humphrey; W Feniuk; A D Watts
Journal:  J Pharm Pharmacol       Date:  1982-08       Impact factor: 3.765

4.  5-Hydroxytryptamine-induced relaxation of isolated mammalian smooth muscle.

Authors:  W Feniuk; P P Humphrey; A D Watts
Journal:  Eur J Pharmacol       Date:  1983-12-09       Impact factor: 4.432

5.  Receptor binding profile of R 41 468, a novel antagonist at 5-HT2 receptors.

Authors:  J E Leysen; F Awouters; L Kennis; P M Laduron; J Vandenberk; P A Janssen
Journal:  Life Sci       Date:  1981-03-02       Impact factor: 5.037

Review 6.  An analysis of 5-hydroxytryptamine receptors mediating contraction of isolated smooth muscle.

Authors:  W Feniuk
Journal:  Neuropharmacology       Date:  1984-12       Impact factor: 5.250

7.  Receptors for 5-hydroxytryptamine on the sympathetic nerves of the rabbit heart.

Authors:  J R Fozard; A T Ali
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1978 Jan-Feb       Impact factor: 3.000

8.  Discrimination of multiple [3H]5-hydroxytryptamine binding sites by the neuroleptic spiperone in rat brain.

Authors:  N W Pedigo; H I Yamamura; D L Nelson
Journal:  J Neurochem       Date:  1981-01       Impact factor: 5.372

9.  MDL 72222: a potent and highly selective antagonist at neuronal 5-hydroxytryptamine receptors.

Authors:  J R Fozard
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-05       Impact factor: 3.000

10.  5-hydroxytryptamine-induced relaxation of neonatal porcine vena cava in vitro.

Authors:  M A Trevethick; W Feniuk; P P Humphrey
Journal:  Life Sci       Date:  1984-07-30       Impact factor: 5.037

View more
  17 in total

1.  Characterization of an endothelial 5-hydroxytryptamine (5-HT) receptor mediating relaxation of the porcine coronary artery.

Authors:  G J Molderings; G Engel; E Roth; M Göthert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-09       Impact factor: 3.000

2.  Investigations of cardiovascular 5-hydroxytryptamine receptor subtypes in the rat.

Authors:  J R Docherty
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-01       Impact factor: 3.000

3.  Poster communications.

Authors: 
Journal:  Br J Pharmacol       Date:  1993-10       Impact factor: 8.739

4.  Inhibition of serotonin receptor type 1 in acute myeloid leukemia impairs leukemia stem cell functionality: a promising novel therapeutic target.

Authors:  A Etxabe; M C Lara-Castillo; J M Cornet-Masana; A Banús-Mulet; M Nomdedeu; M A Torrente; M Pratcorona; M Díaz-Beyá; J Esteve; R M Risueño
Journal:  Leukemia       Date:  2017-02-14       Impact factor: 11.528

5.  Mediation by 5_hydroxytryptamine of the femoral vasoconstriction induced by acid challenge of the rat gastric mucosa.

Authors:  C H Wachter; A Heinemann; J Donnerer; M A Pabst; P Holzer
Journal:  J Physiol       Date:  1998-06-01       Impact factor: 5.182

6.  Comparative analysis of two types of 5-hydroxytryptamine receptor mediating vasorelaxation: differential classification using tryptamines.

Authors:  G R Martin; P Leff; D Cambridge; V J Barrett
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-10       Impact factor: 3.000

7.  Further characterization, by use of tryptamine and benzamide derivatives, of the putative 5-HT4 receptor mediating tachycardia in the pig.

Authors:  C M Villalón; M O den Boer; J P Heiligers; P R Saxena
Journal:  Br J Pharmacol       Date:  1991-01       Impact factor: 8.739

8.  5-Hydroxytryptamine-induced tachycardia in the pig: possible involvement of a new type of 5-hydroxytryptamine receptor.

Authors:  A H Bom; D J Duncker; P R Saxena; P D Verdouw
Journal:  Br J Pharmacol       Date:  1988-03       Impact factor: 8.739

9.  Reduction of cephalic arteriovenous shunting by ergotamine is not mediated by 5-HT1-like or 5-HT2 receptors.

Authors:  A H Bom; J P Heiligers; P R Saxena; P D Verdouw
Journal:  Br J Pharmacol       Date:  1989-06       Impact factor: 8.739

10.  GR43175, a selective agonist for the 5-HT1-like receptor in dog isolated saphenous vein.

Authors:  P P Humphrey; W Feniuk; M J Perren; H E Connor; A W Oxford; L H Coates; D Butina
Journal:  Br J Pharmacol       Date:  1988-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.